Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 24, 2023

SELL
$1.26 - $2.1 $3,780 - $6,300
-3,000 Reduced 16.94%
14,710 $19,000
Q2 2023

Jul 25, 2023

SELL
$1.56 - $1.84 $6,084 - $7,176
-3,900 Reduced 18.05%
17,710 $31,000
Q1 2023

Apr 14, 2023

BUY
$1.6 - $2.48 $960 - $1,488
600 Added 2.86%
21,610 $35,000
Q4 2022

Feb 08, 2023

SELL
$1.68 - $2.5 $588 - $875
-350 Reduced 1.64%
21,010 $40,000
Q2 2022

Aug 12, 2022

BUY
$3.24 - $5.85 $17,172 - $31,004
5,300 Added 33.0%
21,360 $69,000
Q1 2022

May 11, 2022

BUY
$4.6 - $8.83 $16,560 - $31,788
3,600 Added 28.89%
16,060 $84,000
Q4 2021

Feb 08, 2022

BUY
$7.75 - $10.05 $7,750 - $10,050
1,000 Added 8.73%
12,460 $106,000
Q3 2021

Nov 02, 2021

BUY
$7.78 - $10.0 $3,890 - $5,000
500 Added 4.56%
11,460 $114,000
Q2 2021

Aug 11, 2021

BUY
$9.22 - $14.48 $101,051 - $158,700
10,960 New
10,960 $102,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $508M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.